Antiepileptic treatment in patients with epilepsy and other comorbidities

Seizure

Volumn 19, Issue 7, 2010, Pages 375-382

  Ruiz Gimenez J ^a   Sanchez Alvarez J C ^b   Canadillas Hidalgo F ^c   Serrano Castro, P J ^d  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL TORRECÁRDENAS   (Spain)

Author keywords

Anticonvulsants; Comorbidity; Drug interactions; Epilepsy; Guidelines; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; ANTILIPEMIC AGENT; CARBAMAZEPINE; CLOBAZAM; CYCLOSPORIN; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ETHOSUXIMIDE; ETIRACETAM; FOSPHENYTOIN SODIUM; FUROSEMIDE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RAPAMYCIN; SALICYLIC ACID DERIVATIVE; TACROLIMUS; TIAGABINE; TICLOPIDINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; ZONISAMIDE;

ANTICONVULSANT THERAPY; BRAIN TUMOR; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPILEPSY; HEART DISEASE; HEART FAILURE; HUMAN; INFECTION; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MENTAL DISEASE; METABOLIC DISORDER; ORGAN TRANSPLANTATION; PORPHYRIA; PRIORITY JOURNAL; REVIEW; SEIZURE; STROKE; THYROID DISEASE;

EID: 77955984655     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2010.05.008     Document Type: Review

References (76)

1. Tellez-Zenteno JF, Matijevic S, Wiebe S. Somatic comorbidity of epilepsy in the general population in Canada. Epilepsia 2005;46(12):1955-62.
2. Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S. Psychiatric comor-bidity in epilepsy: a population-based analysis. Epilepsia 2007;48(12 (Decem-ber)):2336-44.
3. Gaitatzis A, Carroll K, Majeed A, Sander WJ. The epidemiologyof the comorbidi-ty of epilepsy in the general population. javascript:AL-get (this, 'jour', 'Epilep-sia.'). Epilepsia 2004;45(12):1613-22.
4. Elliott JO, Lu B, Shneker B, et al. Comorbidiy, health screening and quality of life among persons with a story of epilepsy. Epilepsy Behav 2009; (14): 125-9.
5. Ryvlin P. Optimizing therapy of seizures in specific clinical situations. Are the exceptions the rule? Neurology 2006;67(Suppl. 4):S1-2.
6. Hinnell C, Williams J, Metcalfe A, et al. Health status and health-related behaviors in epilepsy compared to other chronic conditions. A national population-based study. Epilepsia 2010 (Article online in advance of print. Published Online: January 7 2010).
7. Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs 2006;15(6 (June)):637-47.
8. NICE. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. October 2004. http://www.ni-ce.org.uk/page.aspx?o=CG020.
9. SIGN. Diagnosis and Management of Epilepsy in adults. A national clinical guideline. April 2003. http://www.sign. ac.uk/pdf/sign70.pdf.
10. Singapore Ministry of Health. Epilepsy in adults. Singapore: Singapore Ministry of Health; 2007 Jan. 43 p. http://www.guideline.gov/summary/pdf.aspx? doc-id =10590&stat=1&string=epilepsy.
11. Clinical guidelines for the management of epilepsy in adults with an intellectual disability. Working Group of the International Association of the Scientific Study of Intellectual Disability. Seizure 2001;10:401-9.
12. Donovan PJ, Cline D. Phenytoin administration by constant intravenous infusion: selective rates of administration. Ann Emerg Med 1991;20(2 (Febru-ary)):139-42.
13. Adams BD, Buckley NH, Kim JY, et al. Fosphenytoin may cause hemodynami-cally unstable bradydisrhythmias. J Emerg Med 2006;30:75-9.
14. Agarwal P, Kumar N, Chandra R, et al. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure 2007;16:527-32.
15. Ramael S, Daoust A, Otoul C, et al. Levetiracetam intravenous infusion: a randomized, placebo controlled safety and pharmacokinetic study. Epilepsia 2006;47:1128-35.
16. Hulhoven R, Rosillon D, Bridson WE, et al. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study. Clin Ther 2008;30(2 (Febru-ary)):260-70.
17. Nau KM, Divertie GD, Valentino AK, et al. Safety and efficacy of levetiracetam for critically ill patients with seizures. Neurocrit Care 2009;11(1):34-7.
18. Kaul S, Meena AK, Murthy JM. Carbamazepine induced bradicardia. Neurol India 2000;48(4):403-4.
19. Murphy N, Mockler M, Ryder M, et al. Decompensation of chronic heart failure associated with pregabalin in patients with neuropathic pain. J Card Fail 2007;13:227-9.
20. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-81.
21. Mehta V, Singhi P, Singhi S. Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. J Child Neurol 2007;22:1191-7.
22. Di Bonaventura C, Mari F, Fattouch J, et al. Use of Levetiracetam in treating epilepsy associated with other medical conditions. Acta Neurol Scand 2006;113:82-6.
23. Shet RD. Metabolic concerns associated with antiepileptics medications. Neurology 2004;63(10 Suppl. 4):S24-9.
24. Ochs HR, Greenblatt DJ, Eckardt B, et al. Repeated diazepam dosing in cirrhotic patients: cumulation and sedation. Clin Pharmacol Ther 1983;33(4):471-6.
25. Gopaul S, Farrell K, Abbot F. Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (e)-2, 4-dieneVPA in people with epilepsy taking VPA. Epilepsia 2003;44(3):322-8.
26. Blio L, Meo R, de Leva MF, et al. Levetiracetam in patients with epilepsy and chronic liver disease: observations in a case series. Clin Neuropharmacol 2008;31(4):221-5.
27. Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure 2006;15:156-64.
28. Brockmoller J, Thomsen T, Wittstock M, et al. Pharmacokinetics of levetirace-tam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B and C): characterization by dynamic liver function tests. Clin Pharmacol Ther 2005;77:529-41.
29. Gabardi S, Abramson S. Drug dosing in chronic kidney disease. Med Clin North Am 2005;89:645-87.
30. Vulliemoz S, Iwanowski P, Landis T, et al. Levetiracetam accumulation in renal failure causing myoclonic encephalopathy with triphasic waves. Seizure 2000;18(5 June):376-8.
31. Israni RK, Kasbekar N, Haynes K, et al. Use of antiepileptic drugs in patients with kidney disease. Sem Dialysis 2006;19:408-16.
32. Vega D, Maalouf NM, Sakhaee K. Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opin Drug Saf 2007;6(5 (Septem-ber)):547-57.
33. Faught E. Review of Unites States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure 2004; 135: S59-65.
34. Hahn M, Gildemeister OS, Krauss GL, et al. Effects of new anticonvulsant medications on porphyrin synthesis in cultured liver cells: potential implications for patients with acute porphyria. Neurology 1997;49:97-106.
35. Bernadette GH, Rieck K, Runge U. Oxcarbacepine in focal epilepsy and hepatic porphyria: a case report. Epilepsia 2001;42:793-5.
36. Zaatreh MM. Levetiracetam in porphyric status epilepticus: a case report. Clin Neuropharmacol 2005;28:243-4.
37. Glass GA, Stankiewicz J, Mithoefer A. Levetiracetam for seizures after liver transplantation. Neurology 2005;64:1084-5.
38. Bjornsonn E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand 2008;118(5 (November)):281-90.
39. Focosi D, Kast RE, Benedetti E, et al. Phenobarbital-associated bone marrow aplasia: a case report and review of the literature. Acta Haematol 2008;119:18-21.
40. Simko J, Horacek J. Carbamazepine and risk of hypothyroidism: a prospective study. Acta Neurol Scand 2007;116:317-21.
41. Ericsson UB, Bjerre I, Forsgren M, et al. Thyroglobulin and thyroid hormones in patients on long-term treatment with phenytoin, carbamazepine, and valproic acid. Epilepsia 1985;26:594-6.
42. Vainionpää LK, Mikkonen K, Rattyä J, et al. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication. Epilepsia 2004;45:197-203.
43. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61:246-55.
44. Pack AM, Morrell MJ, Randall A, et al. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 2008;70:1586-93.
45. Ensrud KE, Walczak TS, Blackwell TL, et al., Osteoporotic Fractures in Men (MrOS) Study Research Group. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology 2008;71:723-30.
46. Ben-Menachem E. Weight issues for people with epilepsy. A review. Epilepsia 2007;48(Suppl. 9):S42-5.
47. Luef G, Abraham I, Hoppichler F, et al. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism 2002;51:1274-8.
48. Bhigjee AI, Rosemberg S. Optimizing therapy of seizures in patients with HIV and cysticercosis. Neurology 2006;67(Suppl. 4):S19-22.
49. Maggi JD, Halman MH. The effect of divalproex sodium on HIV replication in vivo. J Neuropsychiatry Clin Neurosci 2007;19(3 (Summer)):326-30.
50. Lehrman G, Hogue B, Palmer SA, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005;366:549-55.
51. Sagot-Lerolle N, Lamine A, Chaix ML, et al. ANRS EP39 study. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 2008;22:1125-9.
52. Desai J. Perspectives on interactions between antiepileptic drugs (AEDs) and antimicrobial agents. Epilepsia 2008;49(Suppl. 6):S47-9.
53. Beavis J, Kerr M, Marson AG. Pharmacological interventions for epilepsy in people with intellectual disabilities. Cochrane Database Syst Rev 2007;18(3):CD005399.
54. Huber B, Hause U, Horstmann V. Seizure freedom with different therapeutic regimens in intellectually disabled epileptic patients. Seizure 2005;14:381-6.
55. Huber B, Bommel W, Hauser I, et al. Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities. Seizure 2004;13:168-75.
56. Coppola G, Verrotti A, Resicato G, et al. Topiramate in children and adolescents with epilepsy and mental retardation: a prospective study on behavior and cognitive effects. Epilpesy Behav 2008;12(2 (February)):253-6.
57. Ovsiew F. Antiepileptic drugs in psychiatry. J Neurol Neurosurg Psychiatry 2004;75:1665-8.
58. Brodtkorb E, Mula M. Optimizing therapy of seizures in adult patients with psychiatric co morbidity. Neurology 2006;67(Suppl. 4):S39-44.
59. Mula M, Monaco F, Trimble MR. Use of psychotropic drugs in patients with epilepsy: interactions and seizure risk. Expert Rev Neurother 2004;4:953-64.
60. Hommet C, Mondon K, Camus V, et al. Epilepsy and dementia in the elderly. Dement Geriatr Cogn Disord 2008;25:293-300.
61. Mendez M, Lim G. Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging 2003;20(11):791-803.
62. Goldstein B. Common drugs may influence motor recovery after stroke. Neurology 1995;45:865-71.
63. Naidech AM, Kreiter KT, Janjua N, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke 2005;36:583-7.
64. Álvarez-Sabin J, Montaner J, Padro L, et al. Gabapentin in late-onset poststroke seizures. Neurology 2002;59:1991-3.
65. Kutlu G, Gomceli YB, Unal Y, et al. Levetiracetam monotherapy for late post-stroke seizures in the elderly. Epilepsy Behav 2008;13:542-4.
66. Belcastro V, Costa C, Galletti F, et al. Levetiracetam in newly diagnosed late-onset post-stroke seizures: a prospective observational study. Epilepsy Res 2008;82(2-3 (December)):223-6 (Epub 2008 September 30).
67. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy. A randomized study of Gabapentin, Lamotrigine, and Carbamazepine. Neurology 2005;64:1868-73.
68. Gilad R, Sadeh M, Rapaport A, et al. Monotherapy of lamotrigine versus carbamacepine in patients with poststroke seizure. Clin Neuropharmacol 2007;30:189-95.
69. Oberdornfer S, Piribauer M, Marosi C, et al. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 2005;72:255-60.
70. Van Breemen M, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms and management. Lancet Neurol 2007;6:421-30.
71. Wick W, Menn O, Meisner C, et al. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? Onkologie 2005;28:391-6.
72. Lim DA, Tarapore P, Chang E, et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neurooncol 2009;93(3 (July)):349-54.
73. Van Breemen MS, Rijsman RM, Taphoorn MJ, et al. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 2009;256(9 (Septem-ber)):1519-26.
74. Maschio M, Dinapoli L, Vidiri A, et al. The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. J Exp Clin Cancer Res 2009;28(6 (May)):60.
75. Novy J, Stupp R, Rossetti AO. Pregabalin in patients with primary brain tumors and seizures: a preliminary observation. Clin Neurol Neurosurg 2009;111(2 (February)):171-3.
76. Maschio M, Dinapoli L, Saveriano F, et al. Efficacy and tolerability of zonisamide as add-on in brain tumor-related epilepsy: preliminary report. Acta Neurol Scand 2009;120(3 (September)):210-2.